CY1126388T1 - Χρηση delgocitinib για την θεραπεια χρονιουεκζεματος χεριων - Google Patents

Χρηση delgocitinib για την θεραπεια χρονιουεκζεματος χεριων

Info

Publication number
CY1126388T1
CY1126388T1 CY20231100643T CY231100643T CY1126388T1 CY 1126388 T1 CY1126388 T1 CY 1126388T1 CY 20231100643 T CY20231100643 T CY 20231100643T CY 231100643 T CY231100643 T CY 231100643T CY 1126388 T1 CY1126388 T1 CY 1126388T1
Authority
CY
Cyprus
Prior art keywords
treatment
hand eczema
delgocitinib
chronic hand
oxopropanenitrile
Prior art date
Application number
CY20231100643T
Other languages
Greek (el)
English (en)
Inventor
Tero WENNBERG
Anders Per SØRENSEN
Original Assignee
Leo Pharma A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55236207&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1126388(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Leo Pharma A/S filed Critical Leo Pharma A/S
Publication of CY1126388T1 publication Critical patent/CY1126388T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Storage Of Fruits Or Vegetables (AREA)
CY20231100643T 2016-01-21 2023-11-10 Χρηση delgocitinib για την θεραπεια χρονιουεκζεματος χεριων CY1126388T1 (el)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16152215 2016-01-21

Publications (1)

Publication Number Publication Date
CY1126388T1 true CY1126388T1 (el) 2026-02-25

Family

ID=55236207

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20231100643T CY1126388T1 (el) 2016-01-21 2023-11-10 Χρηση delgocitinib για την θεραπεια χρονιουεκζεματος χεριων
CY2024037C CY2024037I2 (el) 2016-01-21 2024-12-17 Χρηση delgocitinib για την θεραπεια χρονιουεκζεματος χεριων

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY2024037C CY2024037I2 (el) 2016-01-21 2024-12-17 Χρηση delgocitinib για την θεραπεια χρονιουεκζεματος χεριων

Country Status (31)

Country Link
US (3) US20200397787A1 (cg-RX-API-DMAC10.html)
EP (2) EP4257205A3 (cg-RX-API-DMAC10.html)
JP (1) JP6929860B2 (cg-RX-API-DMAC10.html)
KR (2) KR20180102662A (cg-RX-API-DMAC10.html)
CN (3) CN117159553A (cg-RX-API-DMAC10.html)
AU (3) AU2017209932A1 (cg-RX-API-DMAC10.html)
BR (1) BR112018014769A2 (cg-RX-API-DMAC10.html)
CA (1) CA3010547A1 (cg-RX-API-DMAC10.html)
CY (2) CY1126388T1 (cg-RX-API-DMAC10.html)
DK (1) DK3405197T3 (cg-RX-API-DMAC10.html)
ES (1) ES2963784T3 (cg-RX-API-DMAC10.html)
FI (2) FI3405197T3 (cg-RX-API-DMAC10.html)
FR (1) FR24C1053I2 (cg-RX-API-DMAC10.html)
HR (1) HRP20231448T1 (cg-RX-API-DMAC10.html)
HU (2) HUE064192T2 (cg-RX-API-DMAC10.html)
IL (4) IL320757A (cg-RX-API-DMAC10.html)
LT (2) LT3405197T (cg-RX-API-DMAC10.html)
MX (2) MX394358B (cg-RX-API-DMAC10.html)
NL (1) NL301306I2 (cg-RX-API-DMAC10.html)
NO (1) NO2024058I1 (cg-RX-API-DMAC10.html)
PL (1) PL3405197T3 (cg-RX-API-DMAC10.html)
PT (1) PT3405197T (cg-RX-API-DMAC10.html)
RS (1) RS64798B1 (cg-RX-API-DMAC10.html)
RU (1) RU2018130097A (cg-RX-API-DMAC10.html)
SG (2) SG10202006830WA (cg-RX-API-DMAC10.html)
SI (1) SI3405197T1 (cg-RX-API-DMAC10.html)
SM (1) SMT202300415T1 (cg-RX-API-DMAC10.html)
TW (2) TWI783921B (cg-RX-API-DMAC10.html)
UA (1) UA123780C2 (cg-RX-API-DMAC10.html)
WO (1) WO2017125523A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201804098B (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3968997T3 (fi) * 2019-05-15 2026-06-09 Leo Pharma As Delgositinibin formulaatio voiteen muodossa
CA3210150A1 (en) * 2021-02-02 2022-08-11 Pfizer Inc. Dosing regime for treatment of chronic hand eczema
KR20240027044A (ko) * 2021-07-30 2024-02-29 일라이 릴리 앤드 캄파니 바리시티닙을 사용한 손 습진의 치료
JP2026509302A (ja) 2023-03-17 2026-03-17 レオ ファーマ アクティーゼルスカブ 中等症ないし重症の慢性手湿疹を有する患者における慢性手湿疹を処置する方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI466885B (zh) 2009-07-31 2015-01-01 Japan Tobacco Inc 含氮螺環化合物及其醫藥用途
US20130302298A1 (en) * 2010-11-30 2013-11-14 Bio-K Plus International Inc. Treatment and prevention of eczema
US20140343034A1 (en) * 2013-04-25 2014-11-20 Japan Tobacco Inc. Skin barrier function improving agent

Also Published As

Publication number Publication date
FR24C1053I1 (fr) 2025-02-21
WO2017125523A1 (en) 2017-07-27
SG11201805394QA (en) 2018-08-30
TW201736382A (zh) 2017-10-16
RU2018130097A (ru) 2020-02-21
CN117159554A (zh) 2023-12-05
JP2019502734A (ja) 2019-01-31
MX2018008449A (es) 2018-08-09
TWI841027B (zh) 2024-05-01
US20200397787A1 (en) 2020-12-24
HUS2400045I1 (hu) 2025-01-28
US20230138114A1 (en) 2023-05-04
SG10202006830WA (en) 2020-08-28
AU2022252766B2 (en) 2024-08-29
CY2024037I1 (el) 2026-02-25
JP6929860B2 (ja) 2021-09-01
EP3405197A1 (en) 2018-11-28
CN117159553A (zh) 2023-12-05
FIC20240048I1 (fi) 2024-12-19
AU2024266962A1 (en) 2024-12-19
KR20180102662A (ko) 2018-09-17
AU2017209932A1 (en) 2018-07-05
NO2024058I1 (no) 2024-12-13
UA123780C2 (uk) 2021-06-02
ZA201804098B (en) 2024-10-30
HUE064192T2 (hu) 2024-02-28
EP4257205A2 (en) 2023-10-11
NL301306I2 (nl) 2024-12-30
IL260094A (en) 2018-07-31
US20260216193A1 (en) 2026-07-30
LTPA2024538I1 (cg-RX-API-DMAC10.html) 2025-01-10
HRP20231448T1 (hr) 2024-03-01
CN108472297A (zh) 2018-08-31
RU2018130097A3 (cg-RX-API-DMAC10.html) 2020-05-25
TW202332451A (zh) 2023-08-16
EP4257205A3 (en) 2023-12-20
IL297379A (en) 2022-12-01
NZ743582A (en) 2024-12-20
IL313543A (en) 2024-08-01
LT3405197T (lt) 2023-11-27
CY2024037I2 (el) 2026-02-25
PL3405197T3 (pl) 2024-02-12
EP3405197B1 (en) 2023-09-06
FR24C1053I2 (fr) 2025-12-05
AU2022252766A1 (en) 2022-11-03
IL320757A (en) 2025-07-01
SI3405197T1 (sl) 2024-03-29
CA3010547A1 (en) 2017-07-27
RS64798B1 (sr) 2023-11-30
FI3405197T3 (fi) 2023-11-23
KR20250088666A (ko) 2025-06-17
ES2963784T3 (es) 2024-04-02
BR112018014769A2 (pt) 2018-12-11
TWI783921B (zh) 2022-11-21
PT3405197T (pt) 2023-12-06
SMT202300415T1 (it) 2024-01-10
MX2022005915A (es) 2022-06-27
MX394358B (es) 2025-03-24
DK3405197T3 (da) 2023-11-27

Similar Documents

Publication Publication Date Title
ZA202500997B (en) Benzoxazepin oxazolidinone compounds and methods of use
CL2019000941A1 (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret.
PH12018502102A1 (en) Pyrrolotriazine compounds as tam inhibitors
CL2017001426A1 (es) Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales.
CL2018000292A1 (es) Compuestos farmacéuticos
MX2017009841A (es) 7-bencil-4-(2-metilbencilo) -2,4,6,7,8,9-hexahidroimidazo [1,2-a] pirido [3,4-e] pirimidin-5 (1h) -ona, analogos y sales del mismo y su uso en terapia.
BR112016016844A2 (pt) Compostos heterocíclicos
BR112017003054A2 (pt) compostos de aminopirimidinila como inibidores de jak
PE20171307A1 (es) Compuestos de triazolopirimidina y usos de los mismos
EA201890001A1 (ru) Замещенные гетероциклические производные как ингибиторы циклинзависимой киназы (cdk)
MX2020001236A (es) Compuestos aza biciclicos como agonistas del receptor muscarinico m1.
MX2013001970A (es) Compuestos de pirrolopirimidina y usos de los mismos.
CR20170384A (es) Derivados de nucleosidos sustituidos utiles como agentes antineoplasicos
CL2015002608A1 (es) Compuesto de amino-pirazol y usos medicinales relacionados.
UY35625A (es) Compuestos de tetrahidrocarbazol y carbazol carboxamida sustituidos como inhibidores de quinasa
CL2018000611A1 (es) Sales de un inhibidor de pim quinasa
CY1120602T1 (el) [1,2,4]τριαζολο[4,3-β]πυριδαζινες για χρηση στη θεραπευτικη αντιμετωπιση πολλαπλασιαστικων ασθενειων
ZA201804098B (en) Treatment of hand eczema
MX2018004868A (es) Derivados de la pirrolidina.
CY1122837T1 (el) Θεραπεια της γυροειδους αλωπεκιας
BR112015023078A2 (pt) inibidores de pirrolopirimindina cdk9 quinase
MX2021012874A (es) Tratamiento del lupus eritematoso cutaneo.
MX381873B (es) Derivados sustituidos de 6-(1h-pirazol-1-il)pirimidin-4-amina y usos de los mismos.
MX2018009758A (es) Uso de inhibidores de la actividad o funcion de pi3k para el tratamiento del sindrome primario de sjögren.
EA201892188A1 (ru) Соединения пирролотриазина в качестве ингибиторов tam